Acquisition synergies Aptuit is part of Evotec and has a history of large-scale asset transfers and integrations, including GlaxoSmithKline assets and multiple acquisitions. This presents opportunities to position integrated, end-to-end development services as a seamless extension of Evotec’s platform for potential cross-sell to legacy GSK and SSCI clients or programs that benefited from Aptuit’s expanded capabilities.

Expanded capabilities With offerings spanning Drug Design & Discovery, API Development and Manufacture, Solid State Chemistry, CMC, and GLP/GMP preclinical and IND programs, Aptuit can be pitched as a one-stop shop for mid to late-stage development, appealing to sponsors seeking reduced vendor management and timelines.

Global reach Operations in the US and Europe combined with a broad therapeutic experience enable proposals to multinational biotech and pharma companies looking to consolidate global development work under a single partner, potentially improving transfer speed, regulatory consistency, and compliance.

Quality leadership Aptuit has earned CMO Leadership Awards in Expertise, Quality, and Compatibility and maintains a track record of moving molecules efficiently with low attrition. This can be emphasized to high-trust buyers prioritizing quality, reliability, and a collaborative development culture.

Risk and compliance clarity Recent controversy around animal testing violations could be a gate to address with prospective clients by highlighting enhanced compliance programs, transparent governance, and independent audits, while offering risk-managed solutions and robust GLP/GMP practices to reassure partners.